Condition: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Sponsor: Imunon
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
This description comes directly from the study's public registry record.
Douglas Faller, MD · 609.896.9100 · dfaller@imunon.com
Lauren Musso · 609.896.9100 · lmusso@imunon.com
Always discuss trial participation with your own doctor first.
| Johns Hopkins Medicine SKCCC | Baltimore, Maryland, United States | Completed |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Active Not Recruiting |
| OU Health, Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05739981